title: [Selective progesterone receptor modulators and their therapeutical use].
abstract: Currently developed selective progesterone receptor modulators (SPRMs) are steroid derived compounds with a bulky radical substitution at carbon 11. They interact with progesterone receptor and exert antagonistic or/and agonistic effects. Mifepristone was approved for pregnancy termination and ulipristal acetate as emergency contraception and pharmacological therapy of uterine fibroids. SPRMs inhibit endometrial proliferation and myoma growth, this suggests a therapeutical effect in cases of endometriosis and other estrogen-dependent diseases.
authors.affiliation: Gynekologicko-porodnická Klinika 1. LF UK a Nemocnice Na Bulovce, Praha, Prednosta prof MUDr. M. Halaska, DrSc. driak@seznam.cz
authors.forename: D
authors.initials: D
authors.lastname: Driák
authors.forename: B
authors.initials: B
authors.lastname: Sehnal
authors.forename: I
authors.initials: I
authors.lastname: Svandová
mesh_terms: D000028:Abortion, Induced / Q000379:methods; D004715:Endometriosis / Q000188:drug therapy; D005260:Female; D006727:Hormone Antagonists; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy; D015735:Mifepristone; D009649:Norpregnadienes; D011247:Pregnancy; D011374:Progesterone / Q000819:agonists / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D011980:Receptors, Progesterone / Q000819:agonists / Q000037:antagonists & inhibitors
chemical_list: D006727:Hormone Antagonists; D009649:Norpregnadienes; D011980:Receptors, Progesterone; D015735:Mifepristone; D011374:Progesterone; C555622:ulipristal acetate